RxDoctor Payments DataLook up a doctor →

Matthew Neff

Gastroenterology · Nashville, TNNPI 1801030523

Payments from drug & device makers

$19,177in general payments, 2019–2025

Across 994 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Sanofi$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • QOL Medical, LLC$724
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$1,2006%
  • Speaking & faculty fees$1,1486%
  • Food & beverage$16,79788%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,177 in reported general payments places this provider in the 80th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$98,965
Medicare patients
349
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib26$163,938
LinzessLinaclotide77$81,304
MotegrityPrucalopride Succinate19$19,770
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates164$10,130
MovantikNaloxegol Oxalate16$6,563
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,591
Pantoprazole Sodium153$2,011
Mycophenolate Mofetil11$1,609
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl27$431
Ondansetron OdtOndansetron24$342
Dicyclomine Hcl15$231
Ondansetron Hcl24$214
Amitriptyline Hcl15$191
Metoclopramide Hcl14$135
Famotidine21$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$6,340$245,242103 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,632$19,77019 claims
Redhill Biopharma Inc.Movantik$109$6,56316 claims
Braintree Laboratories, Inc.Sutab$15$2,59116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →